🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New research assistant position available! Join us! See haqlab.dana-farber.org/join-us.html

NHL fan spotted staffer’s mole from the stands. Now he’s cancer-free, and she has a scholarship to med school. washingtonpost.com/sports/2022/01…

We have just opened a search for two lab-based faculty positions Dana-Farber Harvard Medical School. Any area of cancer research interest is fair game and MD, PhD, or MD/PhD are encouraged to apply. Please pass on: nejmcareercenter.org/job/467547/lab…

PASPCR is starting a monthly seminar series! Our first talk will be with Dr. Deborah Lang from Boston University. Join us on January 18th! bumc.bu.edu/busm/profile/d…

Great news!!

New Dana-Farber Division of Cancer Genetics and Prevention positions for two medical geneticists or medical oncologists! Info below, please share: careercenter.asco.org/job/7613834/me…

Thrilled to share our review in Cancer Discovery with Joan Montero which discusses anti-apoptosis inhibitors (BH3 mimetics) in cancer. aacrjournals.org/cancerdiscover…

We argue that pre-treatment markers do not predict responses to these agents, but adaptive responses must be recognized and targeted to achieve meaningful responses to BH3 mimetics. Thanks to Melanoma Research for their support.

In the May issue of Cancer Discovery, Adapted to survive: targeting cancer cells with BH3 mimetics by Joan Montero and Riz Haq MD PhD. bit.ly/3N6GYUw Dana-Farber Harvard Medical School IBEC

Hope you can join us. Should be a great event for uveal melanoma patients and their families/caregivers. x.com/MRFCureOM/stat…

Now online in Cancer Discovery: A Next-Gen #BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients w/BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation - by Rona Yaeger, S. Michael Rothenberg, et al. doi.org/10.1158/2159-8… Memorial Sloan Kettering Cancer Center Pfizer Oncology Medical

For #ScienceSunday, Dr. Haq from Dana-Farber & one of the recipients of our inaugural Options Bring Hope Team award, speaks with our attendees about his award winning research titled “Identification of Molecular pathways that drive uveal melanoma Metastasis.” #EyeGetDilated #OM

Our paper on a new mechanism of resistance to immunotherapy in melanoma is now in print Cancer Cell with the Van Allen lab Eli Van Allen cell.com/cancer-cell/fu… Details of the paper below

1/Although some patients with metastatic melanoma experience durable responses to immune checkpoint inhibitors, most exhibit intrinsic or acquired resistance to these therapies.

2/Over several years, we collected matched pre-treatment and post-resistance tumor biopsies in patients with metastatic melanoma who exhibited heterogeneous ICI responses to nominate additional mediators of acquired resistance.

3/Strikingly, we found resistance-associated mutations in SEC24C and SEC24D in 3 patients. Melanoma cells engineered to express the SEC24C mutations observed in patients exhibit diminished STING signaling, including decreased Type I interferon production, antigen presentation

4/and a reduced capacity to activate cytotoxic T cells.

5/The project was only possible because of collaboration with the Van Allen lab, talented co-first authors Julia Schiantarelli, Mouadh Benamar, Jihye Park. I am also grateful to patients who donated biopsy material and funding sources, including Melanoma Research Dana-Farber News

We’re hiring post-docs! Join our lab on projects involving immunotherapy and therapy resistance and metastasis in cutaneous and uveal melanoma. Please DM if interested!